ENX-102 is under clinical development by Engrail Therapeutics and currently in Phase I for Generalized Anxiety Disorder (GAD). According to GlobalData, Phase I drugs for Generalized Anxiety Disorder (GAD) have a 79% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ENX-102’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ENX-102 overview

ENX-102 is under development for the treatment of generalized anxiety disorder. The drug candidate acts by targeting gamma-aminobutyric acid type A receptor subunit (GABA(A) receptor or GABR).

Engrail Therapeutics overview

Engrail Therapeutics (Engrail) acquires, develops and commercializes medicines to treat central nervous system diseases. The company is ialso nvestigating ENX-101, a sub-type selective GABA A (?-Aminobutyric acid type A) receptors targeting neurological indications. It is funded by Nan Fung Life Sciences (NFLS). Engrail is headquartered in San Diego, California, the US.

For a complete picture of ENX-102’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.